Trial Profile
A Single Center, Randomized, Open Label, Parallel Group, Phase 3 Study to Evaluate the Efficacy of Dapagliflozin in Subjects With Nonalcoholic Fatty Liver Disease
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 11 Apr 2022
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Adverse reactions
- 11 Apr 2022 New trial record